# US 2024/0191193 A1 · Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0191193 A1
- Document ID: US20240191193A1
- Status: Published application
- Kind: A1
- Application number: 18/584,070
- Filed: 2024-02-22
- Published: 2024-06-13
- Earliest claimed: 2009-05-18
- Assignees: Mallinckrodt Pharmaceuticals Ireland Limited
- Applicants: Mallinckrodt Pharmaceuticals Ireland Limited
- Inventors: Tinghua Cao; Li Li
- Web page: https://patentgrep.com/patent/US20240191193A1

## CPC

- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- C12N 5/0636: {T lymphocytes}
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- C12N 2501/23: Interleukins [IL]
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods for the ex-vivo expansion of CD4+CD25+ Tregs. The invention provides a method for producing ex vivo expanded Tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens. Additionally, the ex vivo expanded Tregs may provide treatment for inflammatory/autoimmune diseases.

## Claims

### Claim 1

A method of preparing a population of cells, the method comprising:
a) obtaining a population of T cells from an individual with an immune-mediated disease selected from Systemic Lupus Erythematous, Multiple Sclerosis, asthma, Rheumatoid Arthritis, Crohn's Disease, or Ulcerative Colitis;
b) isolating and purifying from the T cell population a subpopulation of CD4+CD25+ Tregs; and
c) expanding the Treg cells of the subpopulation over 1,000 fold, in the presence of IL-2, anti-CD3 antibodies, and anti-CD28 antibodies, wherein the expanded Treg cells exhibit enhanced suppressive activity compared to a population of freshly purified, unexpanded Tregs from the individual;
wherein the anti-CD3 antibodies and anti-CD28 antibodies are immobilized on a three-dimensional solid surface.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immune-mediated disease is Systemic Lupus Erythematous.

### Claim 3 (depends on 1)

The method of claim 1, wherein the immune-mediated disease is Multiple Sclerosis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the immune-mediated disease is asthma.

### Claim 5 (depends on 1)

The method of claim 1, wherein the immune-mediated disease is Rheumatoid Arthritis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the immune-mediated disease is Crohn's Disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the immune-mediated disease is Ulcerative Colitis.

### Claim 8 (depends on 1)

The method of claim 1, wherein the expansion is carried out over a period of about 3 weeks.

### Claim 9 (depends on 1)

The method of claim 1, wherein the three-dimensional solid surface is a bead.

### Claim 10 (depends on 9)

The method of claim 9, wherein a Treg to bead ratio is 1:3.

### Claim 11 (depends on 9)

The method of claim 9, the bead is about 1 to 10 microns in diameter.

### Claim 12 (depends on 9)

The method of claim 9, wherein an anti-CD3 and anti-CD28 antibody ratio on the surface of the bead is from about 1:20 to about 20:1.
